Top Markets
#1 Pleasing Gold Pleasing Gold +1,546.27%
#2 PulseChain PulseChain +55.72%
#3 Ontology Gas Ontology Gas +36.94%
#4 DogBull DogBull +36.89%
#5 BOOK OF MEME BOOK OF MEME +30.55%
#6 Neiro Neiro +21.85%
#7 Collect on Fanable Collect on Fanable +21.43%
#8 Nockchain Nockchain +19.56%
#9 Pump.fun Pump.fun +19.14%
#10 Unit Pump Unit Pump +19.14%
Coin of the day
Pleasing Gold Pleasing Gold
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
TCR2 Therapeutics Inc. TCR2 Therapeutics Inc.

TCR2 Therapeutics Inc.

TCRR
Clasificación en acciones #27037
TCR2 Therapeutics Inc. is a clinical-stage immunotherapy firm focused on... TCR2 Therapeutics Inc. is a clinical-stage immunotherapy firm focused on developing cutting-edge T cell receptor (TCR) therapies for cancer patients. The company's lead investigational treatment, gavo-cel, is a unique mono TCR Fusion Construct T cell (TRuC-T cell) designed to target mesothelin-positive solid tumors. This therapy is currently being evaluated in Phase I/II clinical trials for non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. Furthermore, TCR2 Therapeutics has concluded preclinical development for TC-510, another TRuC-T cell specifically engineered to target mesothelin on solid tumors. They are also advancing TC-520, a CD70-targeting TRuC-T cell designed with fratricide resistance for treating renal cell carcinoma. Founded in 2015, the company, formerly known as TCR2, Inc. until its name change in November 2016, is headquartered in Cambridge, Massachusetts.
Precio por acción
$1.48
Última sincronización: 2023-05-31
Capitalización bursátil
$35.54M
Cambio (1 día)
-5.73%
Cambio (1 año)
0.00%
País
US
Comercio TCR2 Therapeutics Inc. (TCRR)

Categoría

Healthcare
Ratio P/B de TCR2 Therapeutics Inc. (TCRR)
Ratio P/B al 2026 TTM: 0
Según los informes financieros más recientes y el precio de las acciones de TCR2 Therapeutics Inc., el ratio P/B actual (TTM) es 0. Al final de 2026, el ratio P/B era 0.
Historial del ratio P/B de TCR2 Therapeutics Inc. desde 2026 hasta 2026
Ratio P/B al final de cada año
Año Ratio P/B Cambiar
Not enough data for the provided dates.
Ratio P/B de empresas similares o competidoras
Empresa Ratio P/B Diferencia del ratio P/B País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.3419 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.2413 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 2.5054 -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 3.7087 -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH